ArticleChembiochem : a European journal of chemical biology2026
Development of a Self-Adjuvanting Influenza Peptide-Glycolipid Conjugate Inducing CD8
Article in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Beyond α-GalCer: Medicinal Chemistry Insights Driving Structural Evolution of CD1d Ligands.Journal of medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Effective immune activation against infectious diseases is achieved through the coordinated interplay of peptide antigen presentation and adjuvant-mediated stimulation, including lipid antigen-type adjuvants. For optimal immune activation with viral antigens, we applied covalent antigen-adjuvant complexation at the molecular level, which enables refined modulation of immune responses. This antigen-complex strategy was applied to viral peptide antigens containing sequence regions with lower variability, a particularly valuable approach for rapidly mutating viruses such as influenza. To construct these conjugated antigen complex structures, we used α-GalCer as the lipid antigen adjuvant and optimized linker designs that markedly influenced immunomodulatory activity. Using the precisely synthesized antigen complexes along with human leukocyte antigen (HLA)-transgenic mice, we successfully demonstrated selective immune activation, particularly the peptide antigen-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.